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Huntingtin interacting protein 1 (HIP1) is a compo-
nent of clathrin coats. We previously demonstrated that
HIP1 promotes clathrin assembly through its central
helical domain, which binds directly to clathrin light
chains (CLCs). To better understand the relationship
between CLC binding and clathrin assembly we sought
to dissect this interaction. Using C-terminal deletion
constructs of the HIP1 helical domain, we identified a
region between residues 450 and 456 that is required for
CLC binding. Within this region, point mutations
showed the importance of residues Leu-451, Leu-452,
and Arg-453. Mutants that fail to bind CLC are unable to
promote clathrin assembly in vitro but still mediate
HIP1 homodimerization and heterodimerization with
the family member HIP12/HIP1R. Moreover, HIP1 bind-
ing to CLC is necessary for HIP1 targeting to clathrin-
coated pits and clathrin-coated vesicles. Interestingly,
HIP1 binds to a highly conserved region of CLC previ-
ously demonstrated to regulate clathrin assembly.
These results suggest a role for HIP1/CLC interactions
in the regulation of clathrin assembly.
Endocytosis via clathrin-coated pits (CCPs)1 and vesicles
(CCVs) is a major pathway for the internalization of plasma
membrane cargo (1). The formation of CCPs and CCVs is ini-
tiated by the assembly of clathrin triskelia into polyhedral
cages that drive membrane curvature directly or through the
recruitment of proteins that influence membrane dynamics (2).
Clathrin triskelia are composed of three copies of the clathrin
heavy chain (CHC) linked together through a trimerization
domain at their C termini (3). Extending from the trimerization
domain are proximal and distal leg segments that end in a
globular N-terminal domain (3). Clathrin assembly occurs
through multiple weak interactions between the leg segments
(4). There are a variety of proteins that regulate clathrin as-
sembly during endocytosis, most notably the clathrin adaptor
protein 2 (AP-2). Additional assembly proteins include AP180,
epsin, HIP1, and its family member HIP12/HIP1R (5). Each of
these proteins bind directly to clathrin triskelia as well as
membrane phospholipids and these properties contribute to
their ability to stimulate clathrin assembly at specific sites on
the plasma membrane (6–14).
Within triskelia, each CHC is generally thought to be bound
to one of two clathrin light chains (CLCs), CLCa and CLCb.
There is an established role for CLCs in inhibiting clathrin
assembly (15, 16), which may be explained by the orientation of
CLCs on the CHC. Through a domain in the central region,
CLCs bind to the proximal leg of the CHC with their C termini
oriented toward the trimerization domain (17, 18). The N ter-
mini may make a U-turn halfway along the proximal leg fold-
ing back toward the trimerization domain (19) or they may
extend along the proximal leg (20). In either scenario, the
N-terminal region could be oriented on the proximal leg in a
manner that could inhibit the self-association of CHCs neces-
sary for assembly. Interestingly, the N termini of the CLCs
contain a domain that is conserved among all isoforms and
throughout evolution (21) and this domain has been implicated
in the ability of CLCs to regulate clathrin assembly (22).
The identification of binding partners for CHC and CLCs has
allowed for an increased understanding of the regulation of
clathrin assembly but the mechanistic details of this process
remain poorly defined. HIP1 is a newly described component of
the coats of CCVs that binds to the N-terminal domain of the
CHC through a clathrin box sequence LMDMD and to AP-2
through sequences that match consensus AP-2-binding motifs
DPF and FXDXF (10, 23, 24). Through a central helical do-
main, HIP1 binds directly to CLCs and promotes clathrin as-
sembly in vitro (14). The helical region also mediates HIP1
homodimerization and its heterodimerization with HIP12/
HIP1R (14). Like HIP1, HIP12/HIP1R binds to CLCs through
its central helical region and promotes clathrin assembly in
vitro (11, 14). Electron microscopic analysis of the cages formed
by HIP12/HIP1R-mediated assembly reveals that 85% are
60–80 nm in diameter similar to the cages formed with other
assembly proteins such as AP-2 and AP180 (11). Together,
these properties demonstrate a role for HIP1 and HIP12/
HIP1R in the regulation of clathrin assembly.
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To further understand the relationship between the function
of HIP1 to assemble clathrin in vitro and its direct binding to
CLCs, we have identified the sites in HIP1 that mediate CLC
interactions and have generated point mutations that block
CLC binding and in vitro clathrin assembly. Moreover, we have
determined that HIP1 binds to the N-terminal domain of the
CLCs that has been implicated in the regulation of clathrin
assembly. These data further support a role for HIP1 in the
formation of CCPs and CCVs.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—A rabbit polyclonal antibody against
HIP12 and a mouse monoclonal antibody against HIP1 were described
previously (10, 25). Monoclonal antibodies against AP-2, CHC, and the
FLAG and His6 epitope tags were from Affinity Bioreagents, Transduc-
tion Labs, Sigma, and Qiagen, respectively.
DNA Constructs and Recombinant Proteins—GST-HIP1-(276–335),
GST-HIP12-(302–348), GST-HIP1-(336–610), and GST-HIP12-(349–
644) were described previously (10, 14). The following HIP1 and CLCb
GST fusion proteins were created by PCR amplification from full-length
HIP1 cDNA or CLCb cDNA with the appropriate primers (see Table I)
with subsequent cloning into pGEX-4T-1 vectors (Amersham Bio-
sciences): GST-HIP1-(336–546), GST-HIP1-(336–463), GST-HIP1-
(336–456), GST-HIP1-(336–449), GST-HIP1-(336–442), GST-HIP1-
(336–435), GST-HIP1-(436–463), GST-CLCb-(1–228), GST-CLCb-(1–
165), GST-CLCb-(77–228), and GST-CLCb-(90–157). The GST fusion
proteins GST-HIP1-AAA, GST-HIP12-ELL-AAA, GST-HIP12-AAA-
DLL, GST-HIP1-D450A, GST-HIP1-L451A, GST-HIP1-L452A, GST-
HIP1-R453A, GST-HIP1-K454A, GST-HIP1-N455A, and GST-CLCb-
(EED/QQN) were generated by the megaprimer technique (26). A first
step of PCR amplification from either full-length HIP1, HIP12, or CLCb
cDNAs was performed with appropriate primers (see Table I) to gener-
ate the megaprimer for each mutant. A second step of PCR amplifica-
tion from either full-length HIP1, HIP12, or CLCb cDNAs was per-
formed to generate the fragment using the megaprimer generated in
the first PCR and appropriate primers (see Table I), with subsequent
cloning into pGEX-2T or pGEX-4T-1 (Amersham Biosciences). The
GST-CLCb-(20–41) was created by 2 steps of PCR amplification. The
first step generates the templates CLCb-(1–19) and CLCb-(42–228)
with appropriate primers (see Table I) using the full-length CLCb
cDNA. The second step generates the fragment, using the two tem-
plates generated in the first PCR and the appropriate primers (see
Table I) with subsequent cloning into pGEX-4T-1 (Amersham Bio-
sciences). Mammalian expression constructs encoding full-length
FLAG-HIP1 or full-length HA-HIP12 were described previously (10, 14,
25). The DLL to AAA mutation in the FLAG-tagged HIP1 construct was
introduced by subcloning of the appropriate fragment digested from
GST-HIP1-AAA. The GFP-CLCb construct was a generous gift from Dr.
Juan Bonifacino. His6-HIP1-(336–610) was generated by subcloning of
the appropriate fragment from GST-HIP1-(336–610) into pTrcHisA
(Invitrogen). His6-CLCb was described previously (14). All constructs
were confirmed by sequencing.
Binding Assays—HEK-293 cells or HeLa cells were transfected by
calcium phosphate. After 48 h, cells were washed in phosphate-buffered
saline (PBS: 154 mM NaCl, 58 mM NaPO4, pH 7.4) and then lysed in
buffer A (10 mM HEPES-OH, pH 7.4, 0.83 mM benzamidine, 0.23 mM
phenylmethylsulfonyl fluoride, 0.5 g/ml aprotinin, and 0.5 g/ml leu-
peptin) and Triton X-100 was added to a final concentration of 1%.
Lysates were centrifuged at 245,000  gmax for 15 min and the super-
natant was incubated overnight at 4 °C with various GST fusion pro-
teins pre-coupled to glutathione-Sepharose. The beads were subse-
quently washed 3 times in buffer A containing 1% Triton X-100. For
other binding assays, purified His6-tagged fusion protein (15 g) in
buffer A was incubated for 3 h at 4 °C with GST fusion proteins pre-
coupled to glutathione-Sepharose. The beads were subsequently
washed 3 times in buffer A. For all assays, proteins specifically bound
to the beads were eluted with sample buffer and analyzed by SDS-
PAGE and Western blot. Overlays of enriched fractions of coat proteins
prepared from adult rat brain CCVs were performed as described (14,
27).
CCV Purification and Clathrin Assembly Assays—Clathrin from
brain CCVs and CCVs from transfected HEK-293 cells were purified as
described previously (14). Clathrin assembly assays were performed
with 0.5 M purified clathrin and different concentrations (0.5–2 M) of
fusion proteins in a final volume of 90 l of clathrin assembly buffer (10
mM Tris-Cl, pH 8.5). Assembly was conducted at physiological pH and
was initiated at 4 °C by addition of 10 l of 1 M MES, pH 6.5–6.7. The
TABLE I
List of primers used to generate different constructs
Construct PCR product generated Forward primer sequence Reverse primer sequence
GST-HIP1-AAA Megaprimer 5-CCACGCTGCCGCGGCGCGGAAGAATG-3 5-GCGCCCGGGTCATTCTTCAAGCTGGTTCAGG-3
Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3
GST-HIP12-ELL-AAA Megaprimer 5-GGAGGCAGCCGCGGCGGCGGCGCAG-3 5-GCGGAATTCTCAGTCGTCCAGCTTGCTCACG-3
Insert 5-GCGGGATCCAAGGACGACAGGGACCTCC-3
GST-HIP12-AAA-DLL Megaprimer 5-GCACGCGGCGGCGGCCAGAAAGAACG-3 5-GCGGAATTCTCAGTCGTCCAGCTTGCTCACG-3
Insert 5-GCGGGATCCAAGGACGACAGGGACCTCC-3
GST-HIP1-(336–546) Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3 5-GCGCCCGGGTCACAGGCTGCTCCGCTCC-3
GST-HIP1-(336–463) Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3 5-GCGCCCGGGTCAGGACACCTGTTTGGTCACC-3
GST-HIP1-(336–456) Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3 5-GCGCCCGGGTCATGCATTCTTCCGCAGC-3
GST-HIP1-(336–449) Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3 5-GCGCCCGGGTCAAGCGTGGTTCTGAACC-3
GST-HIP1-(336–442) Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3 5-GCGCCCGGGTCAGCTGTACTTCTCCTTTAGC-3
GST-HIP1-(336–435) Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3 5-GCGCCCGGGTCAGCTATATCGCTGTTCATTGG-3
GST-HIP1-(436–463) Insert 5-GCGGGATCCAAGCTAAAGGAGAAGTACAGC-3 5-GCGCCCGGGTCAGGACACCTGTTTGGTCACC-3
GST-HIP1-D450A Megaprimer 5-CCACGCTGCCCTGCTGCG-3 5-GCGCCCGGGTCATTCTTCAAGCTGGTTCAGG-3
Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3
GST-HIP1-L451A Megaprimer 5-CGCTGACGCGCTGCGGAAG-3 5-GCGCCCGGGTCATTCTTCAAGCTGGTTCAGG-3
Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3
GST-HIP1-L452A Megaprimer 5-TGACCTGGCGCGGAAGAATG-3 5-GCGCCCGGGTCATTCTTCAAGCTGGTTCAGG-3
Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3
GST-HIP1-R453A Megaprimer 5-CCTGCTGGCGAAGAATGCAG-3 5-GCGCCCGGGTCATTCTTCAAGCTGGTTCAGG-3
Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3
GST-HIP1-K454A Megaprimer 5-GCTGCGGGCGAATGCAGAG-3 5-GCGCCCGGGTCATTCTTCAAGCTGGTTCAGG-3
Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3
GST-HIP1-N455A Megaprimer 5-GCGGAAGGCTGCAGAGG-3 5-GCGCCCGGGTCATTCTTCAAGCTGGTTCAGG-3
Insert 5-GCGGGATCCAAGGATGAGAAGGGACCAC-3
GST-CLCb-(1–228) Insert 5-GCGGAATTCTCAAGCGATCCGGTTG-3 5-GCGGAATTCTCAGCGGGACAGTGGCG-3
GST-CLCb-(1–165) Insert 5-GCGGAATTCTCAAGCGATCCGGTTG-3 5-GCGGAATTCTCATGGCTGCTGGTAG-3
GST-CLCb-(77–228) Insert 5-GCGGGATCCTTTCAGGAGGCCAACG-3 5-GCGGAATTCTCAGCGGGACAGTGGCG-3
GST-CLCb-(90–157) Insert 5-GCGGGATCCATTGCCCAGGCTGACAG-3 5-GCGGAATTCTCAAGCGATCCGGTTG-3
GST-CLCb-(EED/QQN) Megaprimer 5-GCGGAATTCTCAAGCGATCCGGTTG-3 5-CGCCGGGTTCTGCTGCGCCGCCTCCGG-3
Insert 5-GCGGAATTCTCAGCGGGACAGTGGCG-3
GST-CLCb-(Asp-20–41) Template (1–19) 5-GCGGAATTCTCAAGCGATCCGGTTG-3 5-CGCCGCCTCCGGG-3
Template (42  228) 5-GGAGGCGGCGGAGGGCTTCGGGGC-3 5-GCGGAATTCTCAGCGGGACAGTGGCG-3
Insert 5-GCGGAATTCTCAAGCGATCCGGTTG-3 5-GCGGAATTCTCAGCGGGACAGTGGCG-3
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mixture was kept on ice for 45 min and then centrifuged at 400,000 
gmax for 6 min. The proteins in the supernatant and pellet were sepa-
rated by SDS-PAGE and were detected by Coomassie Blue staining.
Immunofluorescence—HeLa cells were plated on poly-L-lysine-
coated coverslips, transfected with 0.8 g of DNA with Genejuice
(Novagen) and were processed for indirect immunofluorescence using
standard protocols.
RESULTS
A Motif within the Helical Domain of HIP1 Is Necessary for
CLC Binding and Clathrin Assembly—Through its helical do-
main, HIP1 promotes clathrin assembly in vitro and binds
directly to the CLC (14). To better understand the relationship
between these two activities, we sought to identify the CLC-
binding site by designing a series of HIP1 helical domain dele-
tion constructs that were expressed as GST fusion proteins
(Fig. 1A) and tested for binding to CLCb in pull-down assays.
Sequential deletion of residues from 610 to 456 does not mark-
edly affect the binding of HIP1 to CLCb (Fig. 1B). Although
slightly lower levels of binding were observed for GST-HIP1-
(336–463) and GST-HIP1-(336–456) compared with the full-
length helical domain, this is likely because of the lower levels
of fusion protein expressed for these constructs (Fig. 1B). In
contrast, deletion to residues 449, 442, or 435 abolishes CLCb
interactions (Fig. 1B). These data suggest a CLC-binding site
in HIP1 between residues 449 and 456. Surprisingly, GST-
HIP1-(436–463) containing this site does not bind to CLCb
(data not shown), suggesting that a region upstream of residue
436 is also necessary for CLCb binding.
We next tested whether HIP1 deletion constructs promote
clathrin assembly in vitro. GST-HIP1-(336–546) and GST-
HIP1-(336–463), which bind to CLCb stimulate clathrin as-
sembly, whereas GST-HIP1-(336–435) neither binds to CLCb
nor promotes assembly (Fig. 1C and data not shown). We also
performed assembly assays with GST-HIP1-(276–335) and
GST-HIP12-(302–348), two fusion proteins that bind to the
terminal domain of the CHC (10, 14). Neither construct pro-
motes assembly (Fig. 1C), demonstrating that GST fusion pro-
tein binding to clathrin is by itself not sufficient to cause
clathrin sedimentation. These results provide a correlation be-
tween the ability of HIP1 to bind to CLC and stimulate clathrin
assembly in vitro.
The region between residues 450 and 456 in HIP1 contains
the tripeptide 450DLL. DLL motifs have been implicated in the
clathrin assembly activity of AP180 although this appears to
involve binding to the CHC (28). Sequence alignment of HIP1
with HIP12/HIP1R revealed an ELL tripeptide in HIP12/
HIP1R at position 463 that aligns with the HIP1 450DLL motif,
as well as a DLL tripeptide starting at position 569. We thus
generated GST-HIP1- and GST-HIP12-helical domain fusion
proteins in which the DLL or ELL tripeptides were replaced
with AAA (Fig. 2A). In contrast to GST-HIP1-(336–610) and
GST-HIP12-(349–644), which bind directly to CLCb, mutation
of 450DLL in HIP1 and 463ELL in HIP12 abolish CLCb binding
(Fig. 2B). Mutation of 569DLL in HIP12 has no effect on this
interaction (Fig. 2B). These data suggest that the DLL and
ELL sequences in HIP1 and HIP12/HIP1R, respectively, con-
tribute to CLC binding. To support that the fusion proteins
were properly expressed, we performed pull-down assays with
wild-type and mutant fusion proteins using lysates from cells
transfected with HIP1 or HIP12. Mutation in the CLC-binding
site on HIP1 and HIP12 does not affect the ability of these
fusion proteins to form heterodimers or homodimers (Fig. 2C).
We next tested for the ability of the mutated fusion proteins
to promote clathrin assembly in vitro. GST-HIP1-AAA does not
promote assembly as compared with reactions performed in the
absence of fusion protein, whereas HIP12-AAA-DLL shows
slight assembly activity (Fig. 2D). Both of these constructs
show significantly less assembly activity than GST-HIP12-
ELL-AAA, for which clathrin appears in the pellet fraction at
the expense of the supernatant (Fig. 2D). These results provide
further evidence that HIP1 and HIP12/HIP1R promote clath-
rin assembly through interactions with CLCs.
CLC Interactions Target HIP1 to CCPs and CCVs—We pre-
viously observed that a HIP1 construct lacking the helical
domain failed to enrich on CCVs isolated from transfected
HEK-293 cells (10). To test if the localization of HIP1 is de-
pendent on CLC interactions, we generated full-length HIP1-
450AAA mutants tagged with FLAG. In pull-down assays, Flag-
HIP1-450AAA failed to bind to GST-CLCb, whereas binding was
readily detected for the WT protein (Fig. 3A) and both proteins
bound equally well to a GST construct encoding the -ear of
AP-2 (data not shown). As described previously, Flag-HIP1-
WT, like CHC, is enriched on CCVs isolated from transfected
HEK-293 cells (Fig. 3B). In contrast, Flag-HIP1-450AAA is not
FIG. 1. A region between residues 450 and 456 in the HIP1
helical domain is necessary for CLCb binding and clathrin as-
sembly. A, schematic representation of GST fusion proteins of the
helical domain of HIP1 used for binding and clathrin assembly assays.
B, purified His6-CLCb was incubated with GST or GST-HIP1 fusion
proteins bound to gluthatione-Sepharose beads. The starting material
(SM) equals 1/10th of the amount of His6-CLCb added to the beads. The
amount of His6-CLCb specifically bound to the beads was analyzed by
Western blot using an anti-tetra-His antibody and the level of GST
fusion proteins was revealed by Ponceau S staining. C, clathrin assem-
bly assays were performed with GST-HIP1 and GST-HIP12 fusion
proteins at increasing concentrations. The samples were centrifuged at
high-speed and CHC and GST fusion proteins remaining in the super-
natant were analyzed by SDS-PAGE and Coomassie Blue staining.
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FIG. 2. Conserved residues in HIP1 and HIP12/HIP1R are necessary for CLCb binding and clathrin assembly. A, schematic
representation of GST fusion proteins containing point mutations in the helical domain of HIP1 and HIP12 used for binding and clathrin assembly
assays. B, purified His6-CLCb was incubated with GST or with GST-HIP1 and GST-HIP12 fusion proteins bound to gluthatione-Sepharose beads.
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enriched on CCVs compared with the homogenate. We next
examined the intracellular localization of these constructs in
HeLa cells by immunofluorescence. Flag-HIP1-WT shows a
discrete punctuate staining that is similar to that seen for
endogenous HIP1 (10) and which is highly co-localized with
endogenous AP-2 (-adaptin) at CCPs (Fig. 3C). In contrast,
Flag-HIP1-450AAA has a diffuse distribution displaying little
co-localization with -adaptin (Fig. 3C). Essentially identical
results are obtained using Ds-Red-tagged HIP1 constructs
(data not shown). A slight enrichment of both Flag-HIP1-WT
and Ds-Red-HIP1-WT in a perinuclear pool likely correspond-
ing to the trans-Golgi network was observed in a proportion of
transfected cells (29) and this staining was also lost in 450AAA
mutants (data not shown). These data suggest that the binding
of HIP1 to CLC is necessary for its targeting to CCPs and
CCVs.
HIP1 Binds Directly to the Regulatory Region of the
CLCb—We next sought to identify the binding site for HIP1 on
the CLC. Based on the work of Brodsky and colleagues (17), we
designed various deletion constructs of the CLCb (Fig. 4A) and
tested them for binding to the purified His6-tagged HIP1 heli-
cal domain. As expected, full-length GST-CLCb binds to His6-
HIP1-(336–610) (Fig. 4B). Similar binding is observed for a
C-terminal deletion construct, GST-CLCb-(1–165) (Fig. 4B). In
contrast, a construct with an N-terminal deletion, GST-CLCb-
(77–228), and a construct encoding the CHC binding site, GST-
CLCb-(90–157), fail to bind to HIP1 (Fig. 4B). The N-terminal
segment of CLCb-(1–77) contains a region encompassing resi-
dues 20–41, which has been described previously to be a reg-
ulatory domain for clathrin assembly activity (22). Impor-
tantly, a full-length CLCb construct with a deletion of this
region, GST-CLCb-(20–41), fails to bind HIP1 (Fig. 4B).
Within this domain are 3 acidic residues critically important
for the regulatory activity (22). Interestingly, a GST construct
encoding full-length CLCb, in which these residues are mu-
tated to uncharged residues (GST-CLCb-(EED/QQN)), fails to
The starting material (SM) equals 1/10th of the amount of His6-CLCb added to the beads. The amount of CLCb specifically bound to the beads was
analyzed by Western blot using an anti-tetra-His antibody. C, lysates from HeLa cells transfected with full-length FLAG-tagged-HIP1 or
full-length hemagglutinin (HA)-tagged-HIP12 were incubated with equal amounts of GST or GST-HIP1 and GST-HIP12 fusion proteins bound to
gluthatione-Sepharose beads. Proteins specifically bound to the beads were analyzed byWestern blot with anti-HIP1 or anti-HIP12 antibodies. The
starting material equals 1/10th of the amount of lysate added to the beads. D, clathrin assembly assays were performed with GST or GST-HIP1
and GST-HIP12 fusion proteins as indicated. The samples were centrifuged at high-speed and CHC in the supernatant and pellet were analyzed
by SDS-PAGE and Coomassie Blue staining. The percentage of CHC in the pellet versus the total (supernatant and pellet) was determined by
densitometric scanning for three independent experiments and is expressed as a mean  S.E.
FIG. 3.HIP1 is targeted to CCPs and
CCVs through binding to CLC. A, ly-
sates from HEK-293 cells transfected
with full-length FLAG-tagged-HIP1-WT
or full-length FLAG-tagged-HIP1-450AAA
were incubated with equal amounts of
GST or GST-CLCb-(1–228) fusion protein
bound to gluthatione-Sepharose. The
starting material (SM) equals 1/10th of
the amount of lysate added to the beads.
Proteins specifically bound to the beads
were analyzed by Western blot with an
anti-FLAG antibody. B, crude CCVs were
isolated from HEK-293 cells transfected
with full-length FLAG-tagged-HIP1-WT
or full-length FLAG-tagged-HIP1-
450AAA. Aliquots of various fractions (H,
homogenate; P1, pellet 1; S2, supernatant
2; and CCVs) from the CCV isolation pro-
cedure were analyzed by Western blot
with anti-CHC or anti-FLAG antibodies.
C, HeLa cells were transfected with full-
length FLAG-tagged-HIP1-WT or full-
length FLAG-tagged-HIP1-450AAA. Ex-
pression of the constructs was revealed by
immunofluorescence using an anti-FLAG
antibody in red. The localization of endog-
enous AP-2 was revealed by -adaptin an-
tibody in green. Overlays of the images
and 5 times magnification of specific re-
gions are shown. Scale bars represent 10
and 2 m in the magnified images.
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bind HIP1 (Fig. 4B). To ensure that the CLCb constructs used
in these experiments are functional, we tested them in overlay
assays on purified coat fractions from adult rat brain CCVs. As
shown in Fig. 4C, GST-CLCb-(1–228) recognizes a band that
corresponds to the CHC and a second band that corresponds to
HIP12/HIP1R, the major HIP isoform expressed in adult rat
brain CCVs (14). In contrast, GST-CLCb-(20–41) and GST-
CLCb-(EED/QQN) recognize only the CHC and not HIP12/
HIP1R (Fig. 4B). GST alone does not recognize any proteins
(Fig. 4B). Together, these results suggest that HIP1 and
HIP12/HIP1R bind directly to the regulatory region of the CLC
and are in fact the first binding partners described for this
important domain.
The demonstration that acidic residues in the regulatory
region of CLCb are necessary for HIP1 binding is not obviously
compatible with the observation that DLL residues in HIP1
contribute to CLCb interactions (Fig. 2). We thus decided to
further examine the CLC-binding site in HIP1 by performing
an alanine scan between residues 450 and 456 (DLLRKN).
These mutants were generated as GST fusion proteins in the
context of the helical domain (Fig. 4D) and were tested for
binding to His6-tagged CLCb. Mutation to alanine of residues
Asp-450, Lys-454, and Asn-455 have no effect on CLCb binding
(Fig. 4E). In contrast, mutation of residues Leu-452 and Arg-
453 abolish and residue Leu-451 reduces CLCb binding (Fig.
4E). Thus, we have identified the residues LLR in the region of
HIP1 from 450 to 456 as important for binding to the CLC. The
sequence 450DLLRKN in HIP1 aligns with the sequence
463ELLRKN in HIP12/HIP1R and mutation in HIP12 of Arg-
466 to alanine also abolishes CLCb binding (data not shown).
DISCUSSION
We have identified a short stretch of amino acids in the
helical domains of HIP1 and HIP12/HIP1R that are critical for
the interaction of these proteins with CLCs. Mutation of these
residues eliminates CLC binding and the ability of the helical
domains to stimulate clathrin assembly in vitro. This supports
that the HIP proteins stimulate clathrin assembly through a
mechanism involving CLC interactions. The Saccharomyces
cerevisiae homologue of the HIPs, Sla2p, also interacts through
its helical domain with CLC although the precise motif medi-
ating binding is unknown (30). Alignment of the helical do-
mains of mammalian HIPs with S. cerevisiae and Schizosac-
charomyces pombe homologues fails to reveal an obvious
sequence motif in the yeast proteins as that identified here.
Thus, the ability of HIP proteins to bind through their helical
domains to CLC is conserved in yeast and human although
whether or not this represents a conserved function in the
regulation of clathrin assembly is unknown.
The assembly of clathrin triskelia occurs through a series of
weak interactions between adjacent proximal and/or distal leg
segments (4). Adaptor proteins such as AP-2, AP180, and epsin
appear to mediate assembly through binding to the terminal
domain of the CHC (7, 9, 13, 28) and a model has been de-
scribed in which these proteins cross-link the terminal domains
of three independent triskelion bringing proximal and distal
legs from adjacent CHCs into proximity (28, 31). It is also well
established that CLCs inhibit clathrin assembly in vitro (15,
16). One model predicts that this occurs through the ability of
CLCs to mask charge interactions needed for CHC self-inter-
action (22). One factor that appears to relieve this inhibitory
FIG. 4. HIP1 binds to the regulatory region of CLCb. A, schematic representation of GST fusion proteins of CLCb used for binding assays.
EED denotes three acidic residues previously shown to be involved in the regulation of clathrin assembly. Ca, Ca2-binding site;HC, CHC-binding
site; N, neuronal-specific insert; Cam, calmodulin-binding site. B, purified His6-HIP1-(336–610) was incubated with equal amounts of various
GST-CLCb fusion proteins bound to gluthatione-Sepharose beads. The amount of HIP1 specifically bound to the beads was analyzed by Western
blot using an anti-tetra-His antibody. The starting material (SM) equals 1/10th of the amount of His6-HIP1-(336–610) added to the beads. C,
purified coat components, chemically stripped from adult rat brain CCVs, were separated by SDS-PAGE and proteins were revealed either by
Western blot with an anti-CHC or anti-HIP12 antibodies or by overlay using GST, GST-CLCb-(1–228), GST-CLCb-(20–41), and GST-CLCb-
(EED/QQN) fusion proteins. D, schematic representation of GST fusion proteins containing point mutations in the helical domain of HIP1 used for
binding assays. E, purified His6-CLCb was incubated with equal amounts of GST or GST-HIP1 fusion proteins bound to gluthatione-Sepharose
beads. The amount of CLCb specifically bound to the beads was analyzed by Western blot using an anti-tetra-His antibody and the level of GST
fusion proteins was revealed by Ponceau S staining. The starting material equals 1/10th of the amount of His6-CLCb added to the beads.
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influence is Ca2, which at relatively high concentrations stim-
ulates assembly (15). Ca2 binds to the CLC through an EF-
hand motif located between residues 85 and 96 and this in-
duces a conformational change that affects CLC interaction
with CHC (21). Our data and that of Chen and Brodsky (46)
suggests that interactions of the HIP proteins with CLCs could
also provide a mechanism to overcome CLC-mediated inhibi-
tion. HIP1 could induce a conformational change affecting the
relationship between CLC and CHC or alternatively, it could
mask the ability of CLCs to disrupt charge interactions be-
tween CHCs. Consistent with the second model, HIP1 binds to
specific acidic residues in a highly conserved domain of the
CLC previously implicated in charge neutralization (22). Arg-
453 and Arg-466, which are required for interaction of HIP1
and HIP12/HIP1R, respectively, with CLC, could contribute to
the neutralization of the overall acidic nature of the conserved
CLC domain, preventing its ability to block CHC self-interac-
tions leading to assembly.
In vivo, the formation of a clathrin coat is a complex process.
Clathrin is recruited to the membrane where it assembles into
a lattice and a series of dynamic rearrangements of clathrin
triskelia occur as the lattice obtains progressively increased
curvature (32). Assembly continues until the deeply invagi-
nated CCP buds from the membrane and the CCV is uncoated
through clathrin dissasembly (5). Not surprisingly, there are
multiple proteins that function in the formation of a clathrin
coat and each may regulate different steps of assembly. Cells
with decreased levels of AP-2 through RNA interference have a
decrease in the number of CCPs at the cell surface and the pits
that remain are smaller (33, 34), suggesting that AP-2 may be
especially important for recruitment and initial lattice forma-
tion. AP180 also contributes to the early formation of a lattice
(35) and it may additionally function to control the size of CCVs
as a mutation affecting its Drosophila homologue, LAP results
in larger synaptic vesicles generated through CCV-mediated
membrane recycling (36). Epsin appears to couple the assembly
of clathrin coats to the generation of membrane curvature
(35, 37).
The stage at which HIP1 functions in clathrin assembly in
vivo is not known. However, we demonstrate that CLC inter-
actions are necessary for the subcellular targeting of HIP1 to
CCPs and CCVs, consistent with the observation that CLCs are
necessary for the ability of HIP12/HIP1R to interact with clath-
rin cages (11). Thus, it is unlikely that HIP1 functions in the
early steps of clathrin recruitment and assembly. It is known
that exchange of clathrin triskelia between cytosolic pools and
clathrin coats, which necessitates ongoing cycles of assembly/
disassembly, is a necessary aspect of the growth phase of clath-
rin coats (38, 39). Disruption of assembly/disassembly cycles
through chemical cross-linking causes an abnormal lattice
structure (40). It is possible that the HIP proteins function in
assembly reactions related to this dynamic exchange process.
Consistent with this notion, RNA interference studies reveal
that CCPs still form at the plasmamembrane in HIP12/HIP1R-
depleted cells, and in fact, there appears to be a more stable
association of clathrin coats with the membrane (41). HIP12/
HIP1R also functions in clathrin-mediated budding at the
trans-Golgi network and as for the plasma membrane, a more
stable association of clathrin coats is seen on the trans-Golgi
network membrane in HIP12/HIP1R-depleted cells (29). Thus,
HIPs could regulate the assembly of clathrin involved in the
growth of a CCP that is needed to make it competent to bud
from the membrane.
The HIP proteins have roles in clathrin-mediated membrane
budding in addition to their function in clathrin assembly. For
example, HIP1 has been proposed to mediate the recruitment
of specific cargo molecules such as neuronal glutamate recep-
tors into CCPs (42). Interestingly, it has been recently demon-
strated that the presence of cargo in CCPs may drive an equi-
librium between coated pit assembly and dissasembly toward
assembly with an increased probability of generating a mature
CCV (43). Stimulation of the assembly activity of HIP1 upon
interaction with cargo could provide a mechanism contributing
to this phenomenon. In addition, HIP12/HIP1R and the yeast
HIP homologue Sla2p are actin-binding proteins. Sla2p dele-
tion in yeast and depletion of HIP12/HIP1R through RNA
interference leads to an enhanced co-localization of actin and
CCVs, suggesting that HIP12/HIP1R and Sla2p are necessary
for a dynamic and productive association of CCVs with the
actin cytoskeleton (29, 41, 44). Overexpression of a region of
CLCb from residues 1 to 44, which contains the HIP12/HIP1R-
binding domain, causes a similar phenotype (46), suggesting
that HIP12/HIP1R could link actin to CCPs through CLC in-
teractions. Given the multiple roles of the HIP proteins in
clathrin-mediated trafficking, it is perhaps not surprising that
their depletion through RNA interference or genetic ap-
proaches causes defects in clathrin-mediated endocytosis (41,
42, 44). Surprisingly, knockdown of both CLCs by RNA inter-
ference fails to block endocytosis of transferrin or epidermal
growth factor receptor (45). However, because CLCs are nor-
mally inhibitory to assembly, their loss of function may not be
manifest as an inhibition of endocytosis similar to what is seen
for loss of HIP proteins. Future studies will examine these
issues and the role of the HIPs in regulating clathrin assembly
in vivo.
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